Phase III study of vadadustat in anaemia due to chronic kidney disease meets primary efficacy endpoint but fails safety endpoint

In this study of patients not on dialysis, vadadustat was non-inferior to darbepoetin alfa for mean change in haemoglobin from baseline to weeks 24-36; however it was not non-inferior for time to first occurrence of major adverse cardiovascular events (no results reported).


Biospace Inc.